fainted; feeling dizzy; Shortness of breath; This serious case was reported by a consumer via call center representative and described the occurrence of fainting in a 66-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix with an associated reaction of no adverse event (1st dose received in OCT-2024). On 03-JAN-2025, the patient received the 2nd dose of Shingrix (intramuscular, left deltoid). On 05-JAN-2025, 2 days after receiving Shingrix, the patient experienced fainting (Verbatim: fainted) (serious criteria GSK medically significant and other: serious as per reporter), dizziness (Verbatim: feeling dizzy) (serious criteria other: serious as per reporter) and shortness of breath (Verbatim: Shortness of breath) (serious criteria other: serious as per reporter). On 07-JAN-2025, the outcome of the fainting and dizziness were resolved (duration 2 days). The outcome of the shortness of breath was not resolved. It was unknown if the reporter considered the fainting, dizziness and shortness of breath to be related to Shingrix. The company considered the fainting, dizziness and shortness of breath to be related to Shingrix. Additional Information: GSK Receipt Date: 07-JAN-2025 The patient spouse reported that a patient receiving his 2nd Shingrix vaccine, had no symptoms after the 1st vaccine, however, he did have symptoms after the 2nd vaccine. 48 hours receiving the 2nd vaccine the patient started feeling dizzy, short of breath and fainted. The ambulance was called, and the patient stayed for 12 hours at the hospital, then he was discharged home. The patient continues to have some shortness of breath, but the dizziness and the fainting has subsided. ER (emergency room) visit required.; Sender’s Comments: Syncope, Dizziness and Dyspnoea are unlisted events which, due to the following criteria (strong temporal association) are considered related to GSK vaccine Shingrix.